Sironax Reaches Halfway Mark in Global Obesity Drug Trial

Testing Novel Allosteric NAMPT Activators

Sironax announced on October 13 that its global Phase 2 clinical trial evaluating the oral drug SIR4156 for obesity has successfully reached fifty percent of its target patient enrollment.

The international study, known as the FORGE-LM trial, tests the experimental treatment in combination with semaglutide among adult participants struggling with obesity. Researchers designed the trial as a double-blind, randomized, placebo-controlled, and parallel-group investigation to rigorously measure the drug candidate's safety and efficacy profile.

What Lies Ahead for the FORGE-LM Program?

The trial focuses specifically on SIR4156, which functions as an orally active allosteric NAMPT activator. By administering this compound alongside semaglutide, medical researchers hope to enhance weight management outcomes for patients compared to existing standalone therapies.

Clinical teams across multiple international sites continue to screen and enroll eligible volunteers to complete the second phase of testing. The parallel-group design ensures that researchers can directly compare outcomes between patients receiving the active combination therapy and those given a placebo.

With patient recruitment now standing at the fifty percent milestone, Sironax moves closer to completing the active enrollment phase of the global study. Subsequent data readouts from this trial will determine whether the allosteric NAMPT activator can successfully advance further down the clinical pipeline.

Frequently Asked Questions

What is the primary goal of the FORGE-LM trial? The study evaluates the effectiveness and safety of the oral drug SIR4156 when combined with semaglutide in adults with obesity.

How is the clinical study structured? It operates as a double-blind, randomized, placebo-controlled, and parallel-group global trial with patients currently being actively enrolled.